LI-RADS stands for Liver Imaging Reporting and Data System. It’s a standardized system created by the American College of Radiology (ACR) to interpret, categorize, and report liver lesions seen on imaging in patients at risk for hepatocellular carcinoma (HCC).
What LI-RADS is used for
LI-RADS helps radiologists and clinicians:
- Speak a common language about liver lesions
- Estimate the probability that a lesion is HCC
- Guide clinical management (surveillance vs. diagnosis vs. treatment)
- Improve consistency across CT, MRI, and contrast-enhanced ultrasound (CEUS)
It is primarily used in patients with:
- Cirrhosis
- Chronic hepatitis B
- Prior HCC
The LI-RADS categories
Each liver observation is assigned a category based on imaging features (arterial enhancement, washout, capsule, size, growth, etc.).
| Category | Meaning |
|---|---|
| LR-1 | Definitely benign (e.g., cyst, hemangioma) |
| LR-2 | Probably benign |
| LR-3 | Intermediate probability of HCC |
| LR-4 | Probably HCC |
| LR-5 | Definitely HCC (imaging diagnosis, no biopsy needed) |
| LR-M | Malignant, not specific for HCC (e.g., cholangiocarcinoma) |
| LR-TIV | Tumor in vein (vascular invasion) |
| LR-NC | Not categorizable (poor image quality) |
🔑 LR-5 is critical because it allows a non-invasive diagnosis of HCC, which is accepted by transplant centers and oncology guidelines.
Imaging modalities covered
LI-RADS applies to:
- Multiphasic CT
- MRI (including hepatobiliary contrast agents like gadoxetate)
- Contrast-Enhanced Ultrasound (CEUS)
Each modality has its own LI-RADS algorithm.
Why LI-RADS matters clinically
- Reduces diagnostic ambiguity
- Enables earlier HCC detection
- Aligns radiology with AASLD and transplant criteria
- Supports consistent decision-making across health systems
Core differences at a glance
| Dimension | LI-RADS | AASLD Criteria |
|---|---|---|
| Owner | American College of Radiology (ACR) | American Association for the Study of Liver Diseases |
| Primary audience | Radiologists | Hepatologists / clinicians |
| Purpose | Standardize imaging interpretation & reporting | Define when HCC can be diagnosed & treated |
| Output | Multiple categories (LR-1 → LR-5, LR-M, etc.) | Binary clinical decision: HCC vs not HCC |
| Granularity | High (probability-based spectrum) | Low (actionable thresholds) |
| Imaging modalities | CT, MRI, CEUS | CT & MRI (CEUS varies by guideline version/region) |
| Role in transplant | Provides imaging language | Determines eligibility & pathway |